Liquid biopsy and non-small cell lung cancer: are we looking at the tip of the iceberg?
Cet article passe en revue les applications possibles des biopsies liquides dans le traitement des cancers du poumon non à petites cellules puis analyse leur potentiel et leurs limites pour une utilisation clinique
The possibility to analyse the tumour genetic material shed in the blood is undoubtedly one of the main achievements of translational research in the latest years. In the modern clinical management of advanced non-small cell lung cancer, molecular characterisation plays an essential role. In parallel, immunotherapy is widely employed, but reliable predictive markers are not available yet. Liquid biopsy has the potential to face the two issues and to increase its role in advanced NSCLC in the next future. The aim of this review is to summarise the main clinical applications of liquid biopsy in advanced non-small cell lung cancer, underlining both its potential and limitations from a clinically driven perspective.
British Journal of Cancer , article en libre accès, 2022